{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:27:20Z","timestamp":1787772440086,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pemphigus is a group of auto-immune blistering disorders, characterised clinically by mucocutaneous blisters and erosions and histopathologically by intra-epidermal acantholysis. It was traditionally associated with high morbidity and mortality. The use of rituximab has brought upon a new dawn in the treatment of pemphigus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>A retrospective analysis to ascertain the efficacy, tolerance, adverse effect profile, remission, and relapse with the use of rituximab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>A retrospective analysis of all diagnosed pemphigus patients who received rituximab therapy over a period of 3 years was performed. The patient's baseline characteristics, disease duration, clinical presentations, mucosal involvement, disease-severity assessment, and adverse events with rituximab were noted. The outcomes were evaluated based on the definitions of the disease-outcome parameters as early and late endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 17 pemphigus patients, there were 14 females (82.4%) and three males (17.6%) with a mean age of 35.9 \u00b1 16.5 years (range: 9\u201365 years). Pemphigus vulgaris (PV) was the predominant type in 11 (64.7%) patients. After rituximab infusion, the 17 patients attained the end of consolidation phase (ECP) within 15 days to 3 months, and the mean duration was 1.24 months. The complete remission (CR on\/off) ranged from 0.5 to 35 months, and the mean duration of remission was 21.7 months. Within a median time of 4.2 months, almost 80% patients achieved CR on therapy. Nine (53%) patients were in CR without any therapy till the end of the study period, and eight (47%) were in remission while on minimal therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Rituximab is an efficacious therapeutic agent for pemphigus and is better tolerated and safer to all the previous medications used in the treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_169_22","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T12:13:57Z","timestamp":1716984837000},"page":"477","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Experience of Rituximab Therapy in Pemphigus"],"prefix":"10.4103","volume":"67","author":[{"given":"Ghanshyam","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Rattan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet","family":"Negi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajni","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-45-20240829","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/archderm.1977.01640090084013","article-title":"Immunosuppressants and prednisone in pemphigus vulgaris: Therapeutic results obtained in 63 patients between 1961 and 1975","volume":"113","author":"Lever","year":"1977","journal-title":"Arch Dermatol"},{"key":"R2-45-20240829","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: Mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin Hematol"},{"key":"R3-45-20240829","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4103\/0378-6323.102354","article-title":"Rituximab in pemphigus","volume":"78","author":"Kanwar","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R4-45-20240829","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1111\/j.1468-3083.2011.04391.x","article-title":"Efficacy and safety of rituximab treatment in Indian pemphigus patients","volume":"27","author":"Kanwar","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R5-45-20240829","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: Recommendations by an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R6-45-20240829","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1001\/archdermatol.2011.3320","article-title":"Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: A case series of 9 patients","volume":"148","author":"Matsukura","year":"2012","journal-title":"Arch Dermatol"},{"key":"R7-45-20240829","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R8-45-20240829","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/1096-8652(200102)66:2<142::AID-AJH1032>3.0.CO;2-0","article-title":"Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: Report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL","volume":"66","author":"Heizmann","year":"2001","journal-title":"Am J Hematol"},{"key":"R9-45-20240829","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000253944","article-title":"Pemphigus- A reappraisal of clinical and histological features in Indian patients","volume":"139","author":"Sehgal","year":"1969","journal-title":"Dermatologica"},{"key":"R10-45-20240829","first-page":"106","article-title":"A clinical study of 85 cases of pemphigus","volume":"39","author":"Handa","year":"1973","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R11-45-20240829","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/ijd.14546","article-title":"Rituximab as an adjuvant therapy for pemphigus: Experience in 61 patients from a single center with long-term follow-up","volume":"59","author":"Sharma","year":"2020","journal-title":"Int J Dermatol"},{"key":"R12-45-20240829","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/DDDT.S306046","article-title":"Rituximab therapy for treatment of pemphigus in Southeast Asians","volume":"15","author":"Kanokrungsee","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"R13-45-20240829","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/ccd.ccd_461_18","article-title":"Childhood pemphigus vulgaris: Report of two cases with emphasis on diagnostic approach","volume":"9","author":"Surya","year":"2018","journal-title":"Contemp Clin Dent"},{"key":"R14-45-20240829","first-page":"1","article-title":"Pediatric pemphigus","volume":"1","author":"Gonul","year":"2015","journal-title":"Clin Pediatr Dermatol"},{"key":"R15-45-20240829","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaad.2017.11.024","article-title":"Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center","volume":"78","author":"Vinay","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R16-45-20240829","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus: A prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"R17-45-20240829","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","article-title":"Adjuvant rituximab therapy of pemphigus: A single-center experience with 31 patients","volume":"148","author":"Lunardon","year":"2012","journal-title":"Arch Dermatol"},{"key":"R18-45-20240829","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/jdv.12678","article-title":"An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab","volume":"29","author":"Amber","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R19-45-20240829","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R20-45-20240829","doi-asserted-by":"crossref","first-page":"105948","DOI":"10.1016\/j.ijantimicag.2020.105948","article-title":"A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence","volume":"55","author":"Wang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R21-45-20240829","doi-asserted-by":"crossref","first-page":"104378","DOI":"10.1016\/j.jcv.2020.104378","article-title":"Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study","volume":"127","author":"Nikpouraghdam","year":"2020","journal-title":"J Clin Virol"},{"key":"R22-45-20240829","doi-asserted-by":"crossref","first-page":"102472","DOI":"10.1016\/j.msard.2020.102472","article-title":"Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis","volume":"46","author":"Sahraian","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R23-45-20240829","doi-asserted-by":"crossref","first-page":"e14647","DOI":"10.1111\/dth.14647","article-title":"Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?","volume":"34","author":"Uzuncakmak","year":"2021","journal-title":"Dermatol Ther"},{"key":"R24-45-20240829","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/art.41380","article-title":"Mild course of COVID-19 and spontaneous virus clearance in a patient with depleted peripheral blood b cells due to rituximab treatment","volume":"72","author":"Fallet","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"R25-45-20240829","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejca.2020.06.017","article-title":"Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?","volume":"136","author":"Houot","year":"2020","journal-title":"Eur J Cancer"},{"key":"R26-45-20240829","first-page":"699","article-title":"Immunizations in immunocompromised patients: A guide for dermatologists","volume":"18","author":"Mohme","year":"2020","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_169_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:46:46Z","timestamp":1787770006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_169_22"}},"subtitle":["A Three-Year Retrospective Study from a Sub-Himalayan State"],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_169_22","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}